1st study eyed using iPS for heart disease - (The Japan News via NewsPoints Desk)

  • Osaka University researchers filed with a committee of the university for the world's first clinical study on a heart disease treatment using induced pluripotent stem (iPS) cells, The Japan News reported Friday.

  • If the project is approved, the researchers will file with the government and launch the clinical study in the first half of 2018.

  • The trial will include three participants, aged 18 to 75, with ischaemic cardiomyopathy.

  • Study lead Yoshiki Sawa and colleagues will use iPS cells produced from mature cells of people who have an immunological type that is less likely to cause rejection responses.

  • The iPS cells will be developed into cardiomyocytes, and made into 0.1-millimetre-thick 5-centimetre-diameter sheets of the muscle cells, which will be transplanted into the participants' hearts and their condition will be observed.

  • Specifically, the researchers will see no cancer develops and if the hearts function better.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles